Otrexup (methotrexate) / Assertio - LARVOL DELTA

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: University of Chicago | Trial completion date: Mar 2025 ➔ Mar 2027 | Trial primary completion date: Mar 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • CD22

Drugs for plaque psoriasis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Review • Dermatology • Immunology • Psoriasis

Comparison table: Some drugs for plaque psoriasis. (PubMed, Med Lett Drugs Ther) - No abstract available

Clinical • Journal • Dermatology • Immunology • Psoriasis

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov) - P1/2 | N=15 | Recruiting | Sponsor: University of Chicago | Active, not recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov) - P1/2 | N=15 | Active, not recruiting | Sponsor: University of Chicago | Not yet recruiting ➔ Active, not recruiting | N=33 ➔ 15 | Initiation date: Apr 2025 ➔ Sep 2024

Enrollment change • Enrollment closed • Trial initiation date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: University of Chicago | Trial completion date: May 2026 ➔ Mar 2025 | Trial primary completion date: Jun 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • CD22

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov) - P1/2 | N=33 | Not yet recruiting | Sponsor: University of Chicago | Initiation date: Apr 2024 ➔ Apr 2025

Trial initiation date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov) - P1/2 | N=33 | Not yet recruiting | Sponsor: University of Chicago

New P1/2 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

Inside the Clinic: A Team-Based Approach to Management of GVHD : Episode 5 The GVHD Prophylaxis Landscape (OncLive) - "Mahasweta Gooptu, MD...Some of us will use PT-Cy in high-risk patients where we think they are high risk for developing GVHD or if we are using peripheral blood stem cells. When they used tacrolimus and methotrexate in the ablative setting, we tried to use marrow product because it’s one of the strongest factors which influenced the development of chronic GVHD. But more to come in the ablative space, I think, in the next few years, really cementing what the standard of care would be."

Video

ALL 001: Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: University of Virginia | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2028 ➔ Jul 2026 | Trial primary completion date: Jul 2024 ➔ Jul 2023

Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22

When Treating AD in Children, Experts Consider Adherence, Other Aspects of Treatment (Medscape) - "Despite a lengthy list of promising drugs for AD in late stages of clinical development, the 'oldies but goodies,' remain a reasonable an appropriate initial approach in newly diagnosed infants and children with mild to moderate disease, according to Amy S. Paller, MD..."

Media quote

Patients with lower ra disease activity more likely to achieve remission (Physician’s Weekly) - "After switching from combination therapy to monotherapy, patients with RA with overall lower disease activity (LDA) are more likely to achieve and remain in remission, according to findings from Jeffrey R. Curtis, MD, MS, MPH, and colleagues....Dr. Curtis and colleagues wrote, adding that RF-negative status and lower PtGA scores were strongly linked with remaining in remission/LDA with etanercept monotherapy or methotrexate."

Media quote

Jonathan Coleman, MD, on Neoadjuvant Chemo for Upper-Tract Urothelial Carcinoma - First and only fully accrued prospective study of the treatment for such high-risk patients (MedPageToday) - "Coleman: In short, persistence, evidence, and collaboration. It took nearly a year of repeated discussions with investigators and a relentless effort to develop a trial that was felt to be clinically meaningful and acceptable....The fuel for the journey was the excellent support for clinical research at MSK, a great mentor in Dr. Dean Bajorin, and our amazing, dedicated patients who put their trust in us to try to get them a better outcome with a well-developed, clinically important study."

Interview

The Current State of Muscle-Invasive Bladder Cancer Management - Shilpa Gupta, MD, reviews current therapies and previews the next steps in optimizing survival (MedPageToday) - "At this year's Genitourinary Cancers Symposium Shilpa Gupta, MD...discussed the best approaches to treating muscle-invasive bladder cancer (MIBC)."

Video

ALL 001: Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: University of Virginia | Trial completion date: Nov 2024 ➔ Aug 2028 | Trial primary completion date: Jan 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22

Adalimumab Addition vs. Methotrexate Escalation in Psoriatic Arthritis (RheumNow) - P4 | N=245 | CONTROL | "An interesting study in Lancet Rheumatology shows that psoriatic arthritis patients not responding to methotrexate alone can respond after adding or escalating adalimumab (ADA) on top of methotrexate (MTX) to reach minimal disease activity (MDA) response....This study suggests it would be wiser to add adalimumab, over escalating methotrexate, in PsA patients not responding to an initial methotrexate course."

P4 data

Methotrexate Plus Leflunomide Proves Effective for PsA (Medscape) - "'I think we probably underutilize leflunomide,' Arthur Kavanaugh...told Medscape Medical News. 'Sometimes medicines get 'old,' for lack of a better term, and fall a little bit of out of favor, sometimes unnecessarily. Leflunomide falls into that category. Because it's older, it doesn't get as much buzz as what's new and shiny....'Even though this was a small study,' he added, 'it brings us right back to: We should really consider leflunomide in the treatment of PsA.'"

Media quote

Downside of Holding Methotrexate with COVID-19 Vaccination (RheumNow) - "A recent prospective, randomized, blinded clinical trial has shown that a 2 week hold of methotrexate (MTX) following COVID-19 (Sinovac-CoronaVac) vaccination resulted in greater anti-SARS-CoV-2 immunogenicity; but there was an increase in flare rates after the second dose of vaccine....Shared decision making and discussion of the possibility of flares is advised."

Online posting

Methotrexate Side Effects (RheumNow) - "Data came from the UK Rheumatoid Arthritis Medication Study (RAMS), a prospective cohort of early RA patients starting methotrexate (MTX) shows that in the first year, adverse events (AE) were common, but not serious....Overall MTX discontinuations were uncommon and fewer than LEF were discontinued."

Online posting

Expanded Table: Some conventional DMARDs for rheumatoid arthritis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Dr Hamilton Talks Tacrolimus Plus Mexotrexate With or Without Mycophenolate Mofetil for GVHD (Oncology Learning Network) - "Betty Hamilton, MD, shares results of a randomized non-inferiority trial comparing tacrolimus/methotrexate versus tacrolimus/reduced-dose methotrexate and mycophenolate mofetil for the prevention of GVHD after myeloablative-related and -unrelated allogeneic hematopoietic cell transplantation (HCT). These findings were presented at the 2021 Annual ASH Meeting."

Video

ALL 001: Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: University of Virginia; Trial completion date: Nov 2025 ➔ Nov 2024; Trial primary completion date: Jan 2022 ➔ Jan 2023

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22

Leon Kircik, MD - Does methotrexate work for psoriatic arthritis? (YouTube) - https://www.youtube.com/watch?v=3u0JVtpP0zA

Video

Bruce Sands, MD, on Redefining Combination Therapy in IBD (Gastroenterology Learning Network) - "A hard look at the actual effectiveness of biologics in the treatment of inflammatory bowel disease (IBD) shows that many patients are not achieving remission from Crohn disease and ulcerative colitis (UC) with existing agents, Bruce Sands, MD, MS...'We all realize that we've reached a plateau with the efficacy of our agents in the treatment of IBD,' he said."

Media quote

Methotrexate mainstay: ACR guidelines reaffirm old DMARD as ‘anchor drug’ in RA therapy (Healio) - "'The ACR 2021 recommendations for rheumatoid arthritis treatment continue to reinforce MTX as the anchor drug for patients with moderate-to-high disease activity,' Stanley Cohen...told Healio Rheumatology."

Media quote